Royalty Pharma (RPRX) Other financing activities (2020 - 2026)

Royalty Pharma (RPRX) posted Other financing activities of -$226000.0 for Q1 2026, up 87.37% sequentially from -$1.8 million in Q4 2025.

Royalty Pharma (RPRX) Other financing activities (2020 - 2026) Analysis & Trends

Royalty Pharma has reported Other financing activities for 4 years, with the latest figure at -$226000.0 in Q1 2026.

Quarterly Other financing activities changed N/A year-over-year to -$226000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$2.0 million (down 201700.0% YoY) and the FY2025 annual result came in at -$1.8 million, up 80.17% from the prior year.
Other financing activities grew to -$226000.0 in Q1 2026 per RPRX's latest filing, from -$1.8 million in the prior quarter.
Over five years, Other financing activities peaked at $2000.0 in Q3 2024 and troughed at -$1.8 million in Q4 2025.
A 3-year average of -$503750.0 and a median of -$113500.0 in 2024 frame the typical range for Other financing activities.
The widest YoY moves for Other financing activities: up 178900.0% in 2025, down 178900.0% in 2025.
Over 3 years, Other financing activities stood at -$1000.0 in 2024, then slumped by 178900.0% to -$1.8 million in 2025, then surged by 87.37% to -$226000.0 in 2026.
According to Business Quant data, Other financing activities over the past three periods registered -$226000.0, -$1.8 million, and -$1000.0 for Q1 2026, Q4 2025, and Q4 2024 respectively.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	128.13 Bn	120.28 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	112.33 Bn	104.33 Bn	3.93 Bn
3	Argenx Se	53.24 Bn	48.05 Bn	1.41 Bn
4	Revolution Medicines	43.64 Bn	43.64 Bn	-
5	BeOne Medicines	39.27 Bn	34.17 Bn	1.53 Bn
6	MindWalk Holdings	35.32 Bn	35.31 Bn	1.82 Bn
7	Royalty Pharma	33.72 Bn	35.84 Bn	-
8	Alnylam Pharmaceuticals	30.58 Bn	27.27 Bn	992.69 Mn
9	Insmed	27.01 Bn	25.85 Bn	358.27 Mn
10	Roivant Sciences	26.16 Bn	26.85 Bn	1.16 Mn

Download Data